Immunotec nominates Mario Paradis to its board of directors

VAUDREUIL-DORION, QUEBEC–(Marketwired – April 28, 2016) – Immunotec Inc. (TSX VENTURE:IMM), a direct-to-consumer company and a leader in the nutritional industry (the “Company” or “Immunotec”), today reported the results of its Annual General Meeting of Shareholders held on April 27, 2016 (“AGM”).

During the AGM, all current directors of the Company were re-elected and Mr. Mario Paradis was newly elected to serve as a director of Immunotec. PricewaterhouseCoopers LLP was reappointed as the Company’s auditor.

Mario Paradis is Vice-President and Chief Financial Officer of Neptune Technologies and Bioressources Inc. and of Acasti Pharma Inc. since 2015. Between 2008 and 2015, Mr. Paradis was Vice-President and Chief Financial Officer at Atrium Innovations Inc., which was acquired in 2014 by corporations backed by the Permira Funds in a transaction valued at over $1.1 billion. Prior to this, Mr. Paradis held roles of increasingly authority at Aeterna Zentaris, most notably as Vice- President Finance and Administration & Corporate Secretary. Mr. Paradis began his career at PricewaterhouseCoopers (PwC), where he successfully held senior positions primarily in audit and tax. Mr. Paradis is a member of the Canadian Chartered Professional Accountants (CPA). He holds a Bachelor’s degree in Business, with a specialty in Accounting, from Universite du Quebec at Trois-Rivieres.

“We are pleased to welcome Mario”, said Rod Budd, Chairman of the Board of Directors. “His experience in the natural health products industry combined with his background as a seasoned accounting and finance executive will be of great value to our Company.”

On April 27, 2016, the Board of Directors of Immunotec also approved the amendment of the Company’s Stock Option Plan (the “Plan”) to allow the automatic extension, for a period of ten (10) business days, to the expiry date of a stock option governed by the Plan if such expiry date falls within a period during which the Company prohibits optionees from exercising their stock options. Such amendment is subject to the approval of the TSX Venture Exchange.